Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP)

被引：0
|
作者：
Hassel, J. [1 ,2 ]
Forschner, A. [3 ]
Bluhm, L. [4 ]
Heinzerling, L. [5 ]
Zimmer, L. [6 ]
Utikal, J. [7 ,8 ]
Kaehler, K. [9 ]
Schlaak, M. [10 ]
Loquai, C. [11 ]
Gutzmer, R. [12 ]
Kieker, F. [13 ]
Berking, C. [14 ]
Bender, A. [15 ]
Schneider, L. [16 ]
Enk, A. [1 ,2 ]
Garbe, C. [3 ]
Weichenthal, M. [9 ]
Schadendorf, D. [6 ]
Hauschild, A. [9 ]
Mohr, P. [4 ]
机构：
[1] Univ Klinikum Heidelberg, Hautklin, Heidelberg, Germany
[2] Univ Klinikum Heidelberg, NCT, Heidelberg, Germany
[3] Univ Klinikum Tubingen, Hautklin, Tubingen, Germany
[4] Elbe Klinikum Buxtehude, Hautklin, Buxtehude, Germany
[5] Univ Klinikum Erlangen, Hautklin, Erlangen, Germany
[6] Univ Klinikum Essen, Hautklin, Essen, Germany
[7] DKFZ, Heidelberg, Germany
[8] Univ Klinikum Mannheim, Klin Kooperat Einheit Dermatoonkol, Heidelberg, Germany
[9] Univ Klinikum Kiel, Hautklin, Kiel, Germany
[10] Univ Klinikum Koln, Hautklin, Cologne, Germany
[11] Univ Klinikum Mainz, Hautklin, Mainz, Germany
[12] Univ Klinikum Hannover, Hautklin, Hannover, Germany
[13] Charite Univ Klinikum, Hautklin, Berlin, Germany
[14] Univ Munchen LMU, Hautklin, Munich, Germany
[15] Univ Klinikum Marburg, Hautklin, Marburg, Germany
[16] Univ Klinikum Ulm, Hautklin, Ulm, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2016年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV19
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [31] Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients
    Dutriaux, Caroline
    Saiag, Philippe
    Meyer, Nicolas
    Khammari, Amir
    Benmahammed, Lynda
    Tadmouri, Abir
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
    Hua, Camille
    Boussemart, Lise
    Mateus, Christine
    Routier, Emilie
    Boutros, Celine
    Cazenave, Hugo
    Viollet, Roxane
    Thomas, Marina
    Roy, Severine
    Benannoune, Naima
    Tomasic, Gorana
    Soria, Jean-Charles
    Champiat, Stephane
    Texier, Matthieu
    Lanoy, Emilie
    Robert, Caroline
    JAMA DERMATOLOGY, 2016, 152 (01) : 45 - 51
  • [33] Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP)
    Lista, A. Gomez de Liano
    Venugopal, B.
    Fife, K.
    Symeonides, S.
    Vasudev, N. S.
    Rudman, S. M.
    Vohra, S.
    Khasati, L.
    Pettinger, C.
    Szabados, B.
    Morrison, L.
    Powles, T.
    Boleti, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 317 - 317
  • [34] Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
    Vitale, Maria Giuseppa
    Scagliarini, Sarah
    Galli, Luca
    Pignata, Sandro
    Lo Re, Giovanni
    Berruti, Alfredo
    Defferrari, Carlotta
    Spada, Massimiliano
    Masini, Cristina
    Santini, Daniele
    Ciuffreda, Libero
    Ruggeri, Enzo Maria
    Bengala, Carmelo
    Livi, Lorenzo
    Fagnani, Daniele
    Bonetti, Andrea
    Giustini, Lucio
    Hamzaj, Alketa
    Procopio, Giuseppe
    Caserta, Claudia
    Sabbatini, Roberto
    PLOS ONE, 2018, 13 (07):
  • [35] Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
    Saiag, P.
    Mortier, L.
    Dutriaux, C.
    Benmahammed, L.
    Morsli, O.
    Train, C.
    Spampinato, A.
    Leccia, M. T.
    Meyer, N.
    Grob, J. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 549 - 549
  • [36] Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program
    Bisschop, Cornelis
    Wind, Thijs T.
    Blank, Christian U.
    Koornstra, Rutger H. T.
    Kapiteijn, Ellen
    Van den Eertwegh, Alfonsus J. M.
    De Groot, Jan Willem B.
    Jalving, Mathilde
    Hospers, Geke A. P.
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (06) : 208 - 214
  • [37] LONG TERM SURVIVAL AND IMMUNOLOGICAL CORRELATES IN METASTATIC MELANOMA TREATED WITH IPILIMUMAB AT 10 MGS WITHIN AN EXPANDED ACCESS PROGRAM
    Di Giacomo, A. M.
    Calabro, L.
    Danielli, R.
    Pesce, I.
    Fonsatti, E.
    Bertocci, E.
    Giannarelli, D.
    Biagioli, M.
    Altomonte, M.
    Maio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 364 - 364
  • [38] Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP)
    Ascierto, Paolo Antonio
    Simeone, Ester
    Chiarion-Sileni, Vanna
    Queirolo, Paola
    Del Vecchio, Michele
    Di Guardo, Lorenza
    Guidoboni, Massimo
    Marchetti, Paolo
    Cappellini, Gian Carlo Antonini
    Ferrucci, Pier Francesco
    Cognetti, Francesco
    Bernengo, Maria Grazia
    Guida, Michele
    Marconcini, Riccardo
    Mandala, Mario
    Parmiani, Giorgio
    Rinaldi, Gaetana
    Aglietta, Massimo
    Calabro, Luana
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] CORRELATES OF OUTCOME IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH DACARBAZINE
    Gao, B.
    Tiley, S. M.
    Gebski, V.
    Mann, G.
    Kefford, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
  • [40] Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP).
    Orlando, M
    Wozniak, A
    Janne, P
    Belani, CP
    Keohan, ML
    Ross, H
    Polikoff, J
    Mintzer, D
    Bloss, L
    Obasaju, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 664S - 664S
12345